HK1200696A1 - 修飾 位點的方法和組合物 - Google Patents
修飾 位點的方法和組合物Info
- Publication number
- HK1200696A1 HK1200696A1 HK15101007.2A HK15101007A HK1200696A1 HK 1200696 A1 HK1200696 A1 HK 1200696A1 HK 15101007 A HK15101007 A HK 15101007A HK 1200696 A1 HK1200696 A1 HK 1200696A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- hprt
- compositions
- modification
- methods
- locus
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
- C12N15/90—Stable introduction of foreign DNA into chromosome
- C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
- C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/10—Transferases (2.)
- C12N9/1048—Glycosyltransferases (2.4)
- C12N9/1077—Pentosyltransferases (2.4.2)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
- C12N9/22—Ribonucleases RNAses, DNAses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/96—Stabilising an enzyme by forming an adduct or a composition; Forming enzyme conjugates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y204/00—Glycosyltransferases (2.4)
- C12Y204/02—Pentosyltransferases (2.4.2)
- C12Y204/02008—Hypoxanthine phosphoribosyltransferase (2.4.2.8)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y301/00—Hydrolases acting on ester bonds (3.1)
- C12Y301/21—Endodeoxyribonucleases producing 5'-phosphomonoesters (3.1.21)
- C12Y301/21004—Type II site-specific deoxyribonuclease (3.1.21.4)
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
- C07K2319/80—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor
- C07K2319/81—Fusion polypeptide containing a DNA binding domain, e.g. Lacl or Tet-repressor containing a Zn-finger domain for DNA binding
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Genetics & Genomics (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Microbiology (AREA)
- Medicinal Chemistry (AREA)
- Biophysics (AREA)
- Physics & Mathematics (AREA)
- Plant Pathology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Enzymes And Modification Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161552309P | 2011-10-27 | 2011-10-27 | |
US201161556691P | 2011-11-07 | 2011-11-07 | |
PCT/US2012/061986 WO2013063315A2 (en) | 2011-10-27 | 2012-10-25 | Methods and compositions for modification of the hprt locus |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1200696A1 true HK1200696A1 (zh) | 2015-08-14 |
Family
ID=48168783
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK15101007.2A HK1200696A1 (zh) | 2011-10-27 | 2015-01-29 | 修飾 位點的方法和組合物 |
Country Status (7)
Country | Link |
---|---|
US (2) | US8895264B2 (zh) |
EP (1) | EP2771457B1 (zh) |
JP (1) | JP6188703B2 (zh) |
AU (1) | AU2012328682B2 (zh) |
CA (2) | CA3099582A1 (zh) |
HK (1) | HK1200696A1 (zh) |
WO (1) | WO2013063315A2 (zh) |
Families Citing this family (115)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10648001B2 (en) | 2012-07-11 | 2020-05-12 | Sangamo Therapeutics, Inc. | Method of treating mucopolysaccharidosis type I or II |
JP6329537B2 (ja) | 2012-07-11 | 2018-05-23 | サンガモ セラピューティクス, インコーポレイテッド | 生物学的薬剤の送達のための方法および組成物 |
ES2613691T3 (es) | 2012-07-11 | 2017-05-25 | Sangamo Biosciences, Inc. | Métodos y composiciones para el tratamiento de enfermedades por almacenamiento lisosomal |
WO2014036219A2 (en) | 2012-08-29 | 2014-03-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
EP3763810A3 (en) | 2012-10-10 | 2021-07-14 | Sangamo Therapeutics, Inc. | T cell modifying compounds and uses thereof |
WO2014089212A1 (en) | 2012-12-05 | 2014-06-12 | Sangamo Biosciences, Inc. | Methods and compositions for regulation of metabolic disorders |
MX2015007550A (es) | 2012-12-12 | 2017-02-02 | Broad Inst Inc | Suministro, modificación y optimización de sistemas, métodos y composiciones para la manipulación de secuencias y aplicaciones terapéuticas. |
WO2014093701A1 (en) | 2012-12-12 | 2014-06-19 | The Broad Institute, Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
CA2901676C (en) | 2013-02-25 | 2023-08-22 | Sangamo Biosciences, Inc. | Methods and compositions for enhancing nuclease-mediated gene disruption |
US9937207B2 (en) | 2013-03-21 | 2018-04-10 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell receptor genes using talens |
CN105518146B (zh) * | 2013-04-04 | 2022-07-15 | 哈佛学院校长同事会 | 利用CRISPR/Cas系统的基因组编辑的治疗性用途 |
US10604771B2 (en) | 2013-05-10 | 2020-03-31 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
CN116083487A (zh) | 2013-05-15 | 2023-05-09 | 桑格摩生物治疗股份有限公司 | 用于治疗遗传病状的方法和组合物 |
CA2915845A1 (en) | 2013-06-17 | 2014-12-24 | The Broad Institute, Inc. | Delivery, engineering and optimization of systems, methods and compositions for targeting and modeling diseases and disorders of post mitotic cells |
JP6702858B2 (ja) | 2013-06-17 | 2020-06-03 | ザ・ブロード・インスティテュート・インコーポレイテッド | ウイルス成分を使用して障害および疾患をターゲティングするためのCRISPR−Cas系および組成物の送達、使用および治療上の適用 |
AU2014281028B2 (en) | 2013-06-17 | 2020-09-10 | Massachusetts Institute Of Technology | Delivery and use of the CRISPR-Cas systems, vectors and compositions for hepatic targeting and therapy |
JP2016528890A (ja) | 2013-07-09 | 2016-09-23 | プレジデント アンド フェローズ オブ ハーバード カレッジ | CRISPR/Cas系を用いるゲノム編集の治療用の使用 |
CA2920899C (en) | 2013-08-28 | 2023-02-28 | Sangamo Biosciences, Inc. | Compositions for linking dna-binding domains and cleavage domains |
DE102013111099B4 (de) * | 2013-10-08 | 2023-11-30 | Eberhard Karls Universität Tübingen Medizinische Fakultät | Permanente Genkorrektur mittels nukleotidmodifizierter messenger RNA |
ES2881473T3 (es) | 2013-10-17 | 2021-11-29 | Sangamo Therapeutics Inc | Métodos de suministro y composiciones para la modificación por ingeniería genética del genoma mediada por nucleasas |
EP3057432B1 (en) | 2013-10-17 | 2018-11-21 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering in hematopoietic stem cells |
KR102431079B1 (ko) | 2013-11-11 | 2022-08-11 | 상가모 테라퓨틱스, 인코포레이티드 | 헌팅턴병을 치료하기 위한 방법 및 조성물 |
WO2015073683A2 (en) * | 2013-11-13 | 2015-05-21 | Children's Medical Center Corporation | Nuclease-mediated regulation of gene expression |
CA2931637C (en) | 2013-12-09 | 2023-10-10 | Sangamo Biosciences, Inc. | Methods and compositions for treating hemophilia |
WO2015089419A2 (en) | 2013-12-12 | 2015-06-18 | The Broad Institute Inc. | Delivery, use and therapeutic applications of the crispr-cas systems and compositions for targeting disorders and diseases using particle delivery components |
CN111206032A (zh) | 2013-12-12 | 2020-05-29 | 布罗德研究所有限公司 | 用于基因组编辑的crispr-cas系统和组合物的递送、用途和治疗应用 |
WO2015117081A2 (en) | 2014-02-03 | 2015-08-06 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a beta thalessemia |
US10370680B2 (en) | 2014-02-24 | 2019-08-06 | Sangamo Therapeutics, Inc. | Method of treating factor IX deficiency using nuclease-mediated targeted integration |
CN106459894B (zh) | 2014-03-18 | 2020-02-18 | 桑格摩生物科学股份有限公司 | 用于调控锌指蛋白表达的方法和组合物 |
CN106687585B (zh) * | 2014-04-14 | 2021-11-02 | 美克斯细胞有限公司 | 用于修饰基因组dna的方法和组合物 |
WO2015164748A1 (en) | 2014-04-24 | 2015-10-29 | Sangamo Biosciences, Inc. | Engineered transcription activator like effector (tale) proteins |
RU2691102C2 (ru) | 2014-05-08 | 2019-06-11 | Сангамо Байосайенсиз, Инк. | Способы и композиции для лечения болезни хантингтона |
EP3142707A4 (en) | 2014-05-13 | 2018-02-21 | Sangamo Therapeutics, Inc. | Methods and compositions for prevention or treatment of a disease |
EP3151846A4 (en) | 2014-06-05 | 2017-12-27 | Sangamo BioSciences, Inc. | Methods and compositions for nuclease design |
WO2016014794A1 (en) | 2014-07-25 | 2016-01-28 | Sangamo Biosciences, Inc. | Methods and compositions for modulating nuclease-mediated genome engineering in hematopoietic stem cells |
US9757420B2 (en) | 2014-07-25 | 2017-09-12 | Sangamo Therapeutics, Inc. | Gene editing for HIV gene therapy |
US9616090B2 (en) | 2014-07-30 | 2017-04-11 | Sangamo Biosciences, Inc. | Gene correction of SCID-related genes in hematopoietic stem and progenitor cells |
CA2960769A1 (en) | 2014-09-16 | 2016-03-24 | Sangamo Therapeutics, Inc. | Methods and compositions for nuclease-mediated genome engineering and correction in hematopoietic stem cells |
MX2017005306A (es) * | 2014-10-23 | 2018-01-09 | Regeneron Pharma | Novedosos sitios de integracion en celulas cho y usos de estos. |
US10889834B2 (en) | 2014-12-15 | 2021-01-12 | Sangamo Therapeutics, Inc. | Methods and compositions for enhancing targeted transgene integration |
WO2016118726A2 (en) | 2015-01-21 | 2016-07-28 | Sangamo Biosciences, Inc. | Methods and compositions for identification of highly specific nucleases |
US11608511B2 (en) | 2015-04-13 | 2023-03-21 | Maxcyte, Inc. | Methods for modifying genomic DNA |
US10179918B2 (en) | 2015-05-07 | 2019-01-15 | Sangamo Therapeutics, Inc. | Methods and compositions for increasing transgene activity |
MX2017014446A (es) | 2015-05-12 | 2018-06-13 | Sangamo Therapeutics Inc | Regulacion de expresion genica mediada por nucleasa. |
US20180289839A1 (en) * | 2015-05-15 | 2018-10-11 | Regents Of The University Of Minnesota | Intranasal therapeutic delivery of adeno-associated virus to central nervous system |
US9957501B2 (en) | 2015-06-18 | 2018-05-01 | Sangamo Therapeutics, Inc. | Nuclease-mediated regulation of gene expression |
CA2991301A1 (en) | 2015-07-13 | 2017-01-19 | Sangamo Therapeutics, Inc. | Delivery methods and compositions for nuclease-mediated genome engineering |
CN108348576B (zh) | 2015-09-23 | 2022-01-11 | 桑格摩生物治疗股份有限公司 | Htt阻抑物及其用途 |
AU2016343887B2 (en) | 2015-10-28 | 2023-04-06 | Sangamo Therapeutics, Inc. | Liver-specific constructs, factor VIII expression cassettes and methods of use thereof |
CA3004349A1 (en) | 2015-11-23 | 2017-06-01 | Sangamo Therapeutics, Inc. | Methods and compositions for engineering immunity |
EP3390437A4 (en) | 2015-12-18 | 2019-10-16 | Sangamo Therapeutics, Inc. | TARGETED DISORDER OF MHC CELL RECEPTOR |
JP7128741B2 (ja) | 2015-12-18 | 2022-08-31 | サンガモ セラピューティクス, インコーポレイテッド | T細胞受容体の標的化破壊 |
CN109152847A (zh) | 2016-01-15 | 2019-01-04 | 桑格摩生物治疗股份有限公司 | 用于治疗神经疾病的方法和组合物 |
EP3769775A3 (en) | 2016-02-02 | 2021-03-17 | Sangamo Therapeutics, Inc. | Compositions for linking dna-binding domains and cleavage domains |
IL264639B2 (en) | 2016-08-24 | 2024-01-01 | Sangamo Therapeutics Inc | Regulation of globulin gene expression using transgenic nucleases with zinc neurites |
KR20220145913A (ko) | 2016-08-24 | 2022-10-31 | 상가모 테라퓨틱스, 인코포레이티드 | 가공된 표적 특이적 뉴클레아제 |
WO2018049009A2 (en) | 2016-09-07 | 2018-03-15 | Sangamo Therapeutics, Inc. | Modulation of liver genes |
CN110022904B (zh) | 2016-10-20 | 2024-04-19 | 桑格摩生物治疗股份有限公司 | 用于治疗法布里病的方法和组合物 |
WO2018081775A1 (en) | 2016-10-31 | 2018-05-03 | Sangamo Therapeutics, Inc. | Gene correction of scid-related genes in hematopoietic stem and progenitor cells |
US11820728B2 (en) | 2017-04-28 | 2023-11-21 | Acuitas Therapeutics, Inc. | Carbonyl lipids and lipid nanoparticle formulations for delivery of nucleic acids |
EP3619322A4 (en) | 2017-05-03 | 2021-06-30 | Sangamo Therapeutics, Inc. | METHODS AND COMPOSITIONS FOR MODIFICATION OF A TRANSMEMBRANARY CONDUCTANCE REGULATORY GENE IN MUCOVISCIDOSIS (CFTR) |
US11512287B2 (en) | 2017-06-16 | 2022-11-29 | Sangamo Therapeutics, Inc. | Targeted disruption of T cell and/or HLA receptors |
JP7410856B2 (ja) * | 2017-07-18 | 2024-01-10 | シーエスエル・ベーリング・ジーン・セラピー・インコーポレイテッド | ドナー改変細胞の選択のための調節可能スイッチ |
WO2019018383A1 (en) | 2017-07-18 | 2019-01-24 | Calimmune, Inc. | COMPOSITIONS AND METHODS FOR TREATING BETA-HEMOGLOBINOPATHIES |
MX2020001177A (es) | 2017-07-31 | 2020-09-25 | Regeneron Pharma | Animales no humanos reporteros de crispr y usos de los mismos. |
SG11201912235PA (en) | 2017-07-31 | 2020-01-30 | Regeneron Pharma | Cas-transgenic mouse embryonic stem cells and mice and uses thereof |
US20190032156A1 (en) | 2017-07-31 | 2019-01-31 | Regeneron Pharmaceuticals, Inc. | Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo |
CA3076036A1 (en) | 2017-09-22 | 2019-03-28 | The Trustees Of The University Of Pennsylvania | Gene therapy for treating mucopolysaccharidosis type ii |
WO2019094725A2 (en) | 2017-11-09 | 2019-05-16 | Sangamo Therapeutics, Inc. | Genetic modification of cytokine inducible sh2-containing protein (cish) gene |
US10610606B2 (en) | 2018-02-01 | 2020-04-07 | Homology Medicines, Inc. | Adeno-associated virus compositions for PAH gene transfer and methods of use thereof |
CN111954540A (zh) | 2018-02-08 | 2020-11-17 | 桑格摩生物治疗股份有限公司 | 工程化靶标特异性核酸酶 |
JP2021514188A (ja) | 2018-02-15 | 2021-06-10 | メモリアル スローン ケタリング キャンサー センター | Foxp3標的因子組成物と養子細胞療法のための使用方法 |
WO2019161365A1 (en) | 2018-02-19 | 2019-08-22 | Homology Medicines, Inc. | Adeno-associated virus compositions for restoring f8 gene function and methods of use thereof |
CA3089331A1 (en) | 2018-03-19 | 2019-09-26 | Regeneron Pharmaceuticals, Inc. | Transcription modulation in animals using crispr/cas systems |
SG11202009446TA (en) | 2018-04-05 | 2020-10-29 | Juno Therapeutics Inc | T cells expressing a recombinant receptor, related polynucleotides and methods |
MA52656A (fr) | 2018-04-05 | 2021-02-17 | Editas Medicine Inc | Procédés de production de cellules exprimant un récepteur recombinant et compositions associées |
CN112313246A (zh) | 2018-04-18 | 2021-02-02 | 桑格摩生物治疗股份有限公司 | 用于调节亨廷顿蛋白(htt)的锌指蛋白组合物 |
US11690921B2 (en) | 2018-05-18 | 2023-07-04 | Sangamo Therapeutics, Inc. | Delivery of target specific nucleases |
SG11202101801RA (en) | 2018-08-23 | 2021-03-30 | Sangamo Therapeutics Inc | Engineered target specific base editors |
EP3849565A4 (en) | 2018-09-12 | 2022-12-28 | Fred Hutchinson Cancer Research Center | REDUCING CD33 EXPRESSION FOR SELECTIVE PROTECTION OF THERAPEUTIC CELLS |
JP2022500052A (ja) | 2018-09-18 | 2022-01-04 | サンガモ セラピューティクス, インコーポレイテッド | プログラム細胞死1(pd1)特異的ヌクレアーゼ |
WO2020069029A1 (en) | 2018-09-26 | 2020-04-02 | Emendobio Inc. | Novel crispr nucleases |
CN113272428A (zh) | 2018-10-18 | 2021-08-17 | 英特利亚治疗股份有限公司 | 核酸构建体和使用方法 |
EP3886869A4 (en) | 2018-11-28 | 2022-07-06 | Forty Seven, Inc. | GENETICALLY MODIFIED CSPH RESISTANT TO ABLATIVE TREATMENT |
AU2020205717A1 (en) | 2019-01-11 | 2021-08-12 | Acuitas Therapeutics, Inc. | Lipids for lipid nanoparticle delivery of active agents |
US20220098621A1 (en) | 2019-02-05 | 2022-03-31 | Emendobio Inc. | Crispr compositions and methods for promoting gene editing of ribosomal protein s19 (rps19) gene |
WO2020163307A1 (en) | 2019-02-06 | 2020-08-13 | Emendobio Inc. | New engineered high fidelity cas9 |
KR20210148154A (ko) | 2019-04-03 | 2021-12-07 | 리제너론 파마슈티칼스 인코포레이티드 | 세이프 하버 좌위 내로의 항체 코딩 서열의 삽입을 위한 방법 및 조성물 |
BR112021021200A2 (pt) | 2019-05-01 | 2021-12-21 | Juno Therapeutics Inc | Células expressando um receptor quimérico de um locus cd247 modificado, polinucleotídeos relacionados e métodos |
CA3136737A1 (en) | 2019-05-01 | 2020-11-05 | Juno Therapeutics, Inc. | Cells expressing a recombinant receptor from a modified tgfbr2 locus, related polynucleotides and methods |
BR112021026832A2 (pt) | 2019-07-02 | 2022-05-10 | Hutchinson Fred Cancer Res | Vetores ad35 recombinantes e aprimoramentos da terapia gênica relacionada |
IL292605A (en) | 2019-11-08 | 2022-07-01 | Regeneron Pharma | CRISPR and AAV strategies for the treatment of x-linked childhood retinoschisis |
WO2021108363A1 (en) | 2019-11-25 | 2021-06-03 | Regeneron Pharmaceuticals, Inc. | Crispr/cas-mediated upregulation of humanized ttr allele |
TW202140791A (zh) | 2020-01-13 | 2021-11-01 | 美商霍蒙拉奇醫藥公司 | 治療苯酮尿症之方法 |
WO2021195079A1 (en) | 2020-03-23 | 2021-09-30 | Regeneron Pharmaceuticals, Inc. | Non-human animals comprising a humanized ttr locus comprising a v30m mutation and methods of use |
WO2021231661A2 (en) | 2020-05-13 | 2021-11-18 | Juno Therapeutics, Inc. | Process for producing donor-batched cells expressing a recombinant receptor |
WO2021260186A1 (en) | 2020-06-26 | 2021-12-30 | Juno Therapeutics Gmbh | Engineered t cells conditionally expressing a recombinant receptor, related polynucleotides and methods |
CN116096702A (zh) | 2020-07-16 | 2023-05-09 | 爱康泰生治疗公司 | 用于脂质纳米颗粒的阳离子脂质 |
EP4240756A1 (en) | 2020-11-04 | 2023-09-13 | Juno Therapeutics, Inc. | Cells expressing a chimeric receptor from a modified invariant cd3 immunoglobulin superfamily chain locus and related polynucleotides and methods |
WO2022204155A1 (en) | 2021-03-23 | 2022-09-29 | Iovance Biotherapeutics, Inc. | Cish gene editing of tumor infiltrating lymphocytes and uses of same in immunotherapy |
CA3232470A1 (en) | 2021-10-27 | 2023-05-04 | Leah SABIN | Compositions and methods for expressing factor ix for hemophilia b therapy |
WO2023081900A1 (en) | 2021-11-08 | 2023-05-11 | Juno Therapeutics, Inc. | Engineered t cells expressing a recombinant t cell receptor (tcr) and related systems and methods |
WO2023108047A1 (en) | 2021-12-08 | 2023-06-15 | Regeneron Pharmaceuticals, Inc. | Mutant myocilin disease model and uses thereof |
WO2023150620A1 (en) | 2022-02-02 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Crispr-mediated transgene insertion in neonatal cells |
WO2023150798A1 (en) | 2022-02-07 | 2023-08-10 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for defining optimal treatment timeframes in lysosomal disease |
WO2023150393A2 (en) | 2022-02-07 | 2023-08-10 | Ensoma, Inc. | Inhibitor-resistant mgmt modifications and modification of mgmt-encoding nucleic acids |
WO2023154861A1 (en) | 2022-02-11 | 2023-08-17 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for screening 4r tau targeting agents |
WO2023220040A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified capsid for gene therapy |
WO2023220035A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus compositions and methods for gene therapy |
WO2023220043A1 (en) | 2022-05-09 | 2023-11-16 | Synteny Therapeutics, Inc. | Erythroparvovirus with a modified genome for gene therapy |
WO2024026474A1 (en) | 2022-07-29 | 2024-02-01 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for transferrin receptor (tfr)-mediated delivery to the brain and muscle |
WO2024073606A1 (en) | 2022-09-28 | 2024-04-04 | Regeneron Pharmaceuticals, Inc. | Antibody resistant modified receptors to enhance cell-based therapies |
US20240182561A1 (en) | 2022-11-04 | 2024-06-06 | Regeneron Pharmaceuticals, Inc. | Calcium voltage-gated channel auxiliary subunit gamma 1 (cacng1) binding proteins and cacng1-mediated delivery to skeletal muscle |
WO2024100604A1 (en) | 2022-11-09 | 2024-05-16 | Juno Therapeutics Gmbh | Methods for manufacturing engineered immune cells |
US20240173426A1 (en) | 2022-11-14 | 2024-05-30 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for fibroblast growth factor receptor 3-mediated delivery to astrocytes |
Family Cites Families (69)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5420032A (en) | 1991-12-23 | 1995-05-30 | Universitge Laval | Homing endonuclease which originates from chlamydomonas eugametos and recognizes and cleaves a 15, 17 or 19 degenerate double stranded nucleotide sequence |
US5487994A (en) | 1992-04-03 | 1996-01-30 | The Johns Hopkins University | Insertion and deletion mutants of FokI restriction endonuclease |
US5356802A (en) | 1992-04-03 | 1994-10-18 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoites (FokI) restriction endonuclease |
US5436150A (en) | 1992-04-03 | 1995-07-25 | The Johns Hopkins University | Functional domains in flavobacterium okeanokoities (foki) restriction endonuclease |
US5792632A (en) | 1992-05-05 | 1998-08-11 | Institut Pasteur | Nucleotide sequence encoding the enzyme I-SceI and the uses thereof |
US6140466A (en) | 1994-01-18 | 2000-10-31 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
US6242568B1 (en) | 1994-01-18 | 2001-06-05 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
CA2681922C (en) | 1994-01-18 | 2012-05-15 | The Scripps Research Institute | Zinc finger protein derivatives and methods therefor |
GB9824544D0 (en) | 1998-11-09 | 1999-01-06 | Medical Res Council | Screening system |
JP4118327B2 (ja) | 1994-08-20 | 2008-07-16 | ゲンダック・リミテッド | Dna認識のための結合タンパク質におけるまたはそれに関連する改良 |
US5789538A (en) | 1995-02-03 | 1998-08-04 | Massachusetts Institute Of Technology | Zinc finger proteins with high affinity new DNA binding specificities |
US5925523A (en) | 1996-08-23 | 1999-07-20 | President & Fellows Of Harvard College | Intraction trap assay, reagents and uses thereof |
GB2338237B (en) | 1997-02-18 | 2001-02-28 | Actinova Ltd | In vitro peptide or protein expression library |
GB9703369D0 (en) | 1997-02-18 | 1997-04-09 | Lindqvist Bjorn H | Process |
GB9710809D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
GB9710807D0 (en) | 1997-05-23 | 1997-07-23 | Medical Res Council | Nucleic acid binding proteins |
US6410248B1 (en) | 1998-01-30 | 2002-06-25 | Massachusetts Institute Of Technology | General strategy for selecting high-affinity zinc finger proteins for diverse DNA target sites |
WO1999045132A1 (en) | 1998-03-02 | 1999-09-10 | Massachusetts Institute Of Technology | Poly zinc finger proteins with improved linkers |
US6140081A (en) | 1998-10-16 | 2000-10-31 | The Scripps Research Institute | Zinc finger binding domains for GNN |
US6453242B1 (en) | 1999-01-12 | 2002-09-17 | Sangamo Biosciences, Inc. | Selection of sites for targeting by zinc finger proteins and methods of designing zinc finger proteins to bind to preselected sites |
US7013219B2 (en) | 1999-01-12 | 2006-03-14 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US7070934B2 (en) | 1999-01-12 | 2006-07-04 | Sangamo Biosciences, Inc. | Ligand-controlled regulation of endogenous gene expression |
US6599692B1 (en) | 1999-09-14 | 2003-07-29 | Sangamo Bioscience, Inc. | Functional genomics using zinc finger proteins |
US6534261B1 (en) | 1999-01-12 | 2003-03-18 | Sangamo Biosciences, Inc. | Regulation of endogenous gene expression in cells using zinc finger proteins |
US6503717B2 (en) | 1999-12-06 | 2003-01-07 | Sangamo Biosciences, Inc. | Methods of using randomized libraries of zinc finger proteins for the identification of gene function |
US6794136B1 (en) | 2000-11-20 | 2004-09-21 | Sangamo Biosciences, Inc. | Iterative optimization in the design of binding proteins |
US7030215B2 (en) | 1999-03-24 | 2006-04-18 | Sangamo Biosciences, Inc. | Position dependent recognition of GNN nucleotide triplets by zinc fingers |
US6689558B2 (en) | 2000-02-08 | 2004-02-10 | Sangamo Biosciences, Inc. | Cells for drug discovery |
US20020061512A1 (en) | 2000-02-18 | 2002-05-23 | Kim Jin-Soo | Zinc finger domains and methods of identifying same |
US20030044787A1 (en) | 2000-05-16 | 2003-03-06 | Joung J. Keith | Methods and compositions for interaction trap assays |
JP2002060786A (ja) | 2000-08-23 | 2002-02-26 | Kao Corp | 硬質表面用殺菌防汚剤 |
US7067317B2 (en) * | 2000-12-07 | 2006-06-27 | Sangamo Biosciences, Inc. | Regulation of angiogenesis with zinc finger proteins |
GB0108491D0 (en) | 2001-04-04 | 2001-05-23 | Gendaq Ltd | Engineering zinc fingers |
US20040224385A1 (en) | 2001-08-20 | 2004-11-11 | Barbas Carlos F | Zinc finger binding domains for cnn |
US7262054B2 (en) | 2002-01-22 | 2007-08-28 | Sangamo Biosciences, Inc. | Zinc finger proteins for DNA binding and gene regulation in plants |
BRPI0307383B1 (pt) | 2002-01-23 | 2019-12-31 | The Univ Of Utah Research Foundation | método de recombinação genética direcionada em célula de planta hospedeira |
WO2003080809A2 (en) | 2002-03-21 | 2003-10-02 | Sangamo Biosciences, Inc. | Methods and compositions for using zinc finger endonucleases to enhance homologous recombination |
US7361635B2 (en) | 2002-08-29 | 2008-04-22 | Sangamo Biosciences, Inc. | Simultaneous modulation of multiple genes |
WO2004037977A2 (en) | 2002-09-05 | 2004-05-06 | California Institute Of Thechnology | Use of chimeric nucleases to stimulate gene targeting |
AU2004208031B2 (en) * | 2003-01-28 | 2009-10-08 | Cellectis | Use of meganucleases for inducing homologous recombination ex vivo and in toto in vertebrate somatic tissues and application thereof. |
US7888121B2 (en) | 2003-08-08 | 2011-02-15 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
US8409861B2 (en) | 2003-08-08 | 2013-04-02 | Sangamo Biosciences, Inc. | Targeted deletion of cellular DNA sequences |
US7972854B2 (en) | 2004-02-05 | 2011-07-05 | Sangamo Biosciences, Inc. | Methods and compositions for targeted cleavage and recombination |
CA2561714A1 (en) | 2004-04-08 | 2005-10-27 | Sangamo Biosciences, Inc. | Methods and compositions for treating neuropathic and neurodegenerative conditions |
EP1737498A2 (en) | 2004-04-08 | 2007-01-03 | Sangamo Biosciences Inc. | Zinc finger proteins for treatment of neuropathic pain |
US20080131962A1 (en) | 2006-05-25 | 2008-06-05 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2006033859A2 (en) | 2004-09-16 | 2006-03-30 | Sangamo Biosciences, Inc. | Compositions and methods for protein production |
US20090068164A1 (en) | 2005-05-05 | 2009-03-12 | The Ariz Bd Of Regents On Behald Of The Univ Of Az | Sequence enabled reassembly (seer) - a novel method for visualizing specific dna sequences |
SG10201508995QA (en) | 2005-07-26 | 2015-11-27 | Sangamo Biosciences Inc | Targeted integration and expression of exogenous nucleic acid sequences |
JP5937292B2 (ja) | 2005-10-18 | 2016-06-22 | デューク大学 | 配列特異性およびdna−結合親和度が変更された、合理設計メガヌクレアーゼ |
AU2007267874B2 (en) | 2006-05-25 | 2012-03-15 | Sangamo Therapeutics, Inc. | Methods and compositions for gene inactivation |
JP5188504B2 (ja) | 2006-11-13 | 2013-04-24 | サンガモ バイオサイエンシズ インコーポレイテッド | ヒトグルココルチコイド受容体遺伝子座の修飾のための方法および組成物 |
BRPI0718747A2 (pt) * | 2006-11-14 | 2013-12-03 | Cellectis | Variantes meganuclease que clavam uma ou sequência alvo de dna a partir do gene hprt e usos das mesmas. |
ATE489465T1 (de) * | 2007-04-26 | 2010-12-15 | Sangamo Biosciences Inc | Gezielte integration in die ppp1r12c-position |
WO2009042163A2 (en) | 2007-09-27 | 2009-04-02 | Sangamo Biosciences, Inc. | Rapid in vivo identification of biologically active nucleases |
WO2009151591A2 (en) * | 2008-06-10 | 2009-12-17 | Sangamo Biosciences, Inc. | Methods and compositions for generation of bax- and bak-deficient cell lines |
CN102159722B (zh) | 2008-08-22 | 2014-09-03 | 桑格摩生物科学股份有限公司 | 用于靶向单链切割和靶向整合的方法和组合物 |
ES2627552T3 (es) | 2008-12-04 | 2017-07-28 | Sigma Aldrich Company | Edición de genoma en ratas usando nucleasas con dedos de cinc |
AU2009333863B2 (en) | 2008-12-17 | 2015-02-05 | Corteva Agriscience Llc | Targeted integration into the Zp15 locus |
EP2206723A1 (en) | 2009-01-12 | 2010-07-14 | Bonas, Ulla | Modular DNA-binding domains |
WO2011011767A1 (en) * | 2009-07-24 | 2011-01-27 | Sigma-Aldrich Co. | Method for genome editing |
US8586526B2 (en) | 2010-05-17 | 2013-11-19 | Sangamo Biosciences, Inc. | DNA-binding proteins and uses thereof |
US8956828B2 (en) | 2009-11-10 | 2015-02-17 | Sangamo Biosciences, Inc. | Targeted disruption of T cell receptor genes using engineered zinc finger protein nucleases |
CN102770539B (zh) | 2009-12-10 | 2016-08-03 | 明尼苏达大学董事会 | Tal效应子介导的dna修饰 |
US8962281B2 (en) | 2010-02-08 | 2015-02-24 | Sangamo Biosciences, Inc. | Engineered cleavage half-domains |
WO2011100058A1 (en) | 2010-02-09 | 2011-08-18 | Sangamo Biosciences, Inc. | Targeted genomic modification with partially single-stranded donor molecules |
LT2566972T (lt) | 2010-05-03 | 2020-03-10 | Sangamo Therapeutics, Inc. | Kompozicijos, skirtos cinko pirštu modulių susiejimui |
US20130171732A1 (en) * | 2011-10-06 | 2013-07-04 | Sangamo Biosciences, Inc. | Methods and compositions for regulating hiv infection |
WO2013123408A1 (en) | 2012-02-17 | 2013-08-22 | Sigma-Aldrich Co. Llc | Cells deficient in hypoxanthine-guanine phosphoribosyltransferase |
-
2012
- 2012-10-25 AU AU2012328682A patent/AU2012328682B2/en active Active
- 2012-10-25 CA CA3099582A patent/CA3099582A1/en active Pending
- 2012-10-25 US US13/660,843 patent/US8895264B2/en active Active
- 2012-10-25 US US13/660,821 patent/US9222105B2/en active Active
- 2012-10-25 EP EP12844270.4A patent/EP2771457B1/en active Active
- 2012-10-25 WO PCT/US2012/061986 patent/WO2013063315A2/en active Application Filing
- 2012-10-25 CA CA2852955A patent/CA2852955C/en active Active
- 2012-10-25 JP JP2014539020A patent/JP6188703B2/ja active Active
-
2015
- 2015-01-29 HK HK15101007.2A patent/HK1200696A1/zh unknown
Also Published As
Publication number | Publication date |
---|---|
EP2771457A4 (en) | 2015-04-08 |
EP2771457B1 (en) | 2017-11-22 |
JP6188703B2 (ja) | 2017-08-30 |
WO2013063315A3 (en) | 2013-06-20 |
JP2014532410A (ja) | 2014-12-08 |
AU2012328682A1 (en) | 2014-05-01 |
AU2012328682B2 (en) | 2017-09-21 |
CA3099582A1 (en) | 2013-05-02 |
CA2852955C (en) | 2021-02-16 |
US8895264B2 (en) | 2014-11-25 |
WO2013063315A2 (en) | 2013-05-02 |
US20130122591A1 (en) | 2013-05-16 |
EP2771457A2 (en) | 2014-09-03 |
US9222105B2 (en) | 2015-12-29 |
US20130137104A1 (en) | 2013-05-30 |
CA2852955A1 (en) | 2013-05-02 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1200696A1 (zh) | 修飾 位點的方法和組合物 | |
HK1202071A1 (zh) | 殺生物劑組成物及其使用方法 | |
EP2736330A4 (en) | COMPOUNDS AND METHODS | |
IL228845A0 (en) | Antimicrobial compounds and methods for their preparation and use | |
EP2747560A4 (en) | CONNECTIONS AND METHODS | |
EP2736332A4 (en) | CONNECTIONS AND METHODS | |
EP2736329A4 (en) | COMPOUNDS AND METHODS | |
ZA201404399B (en) | Bio-pesticide methods and compositions | |
HK1201469A1 (zh) | 用於止血的組合物和方法 | |
EP2858648A4 (en) | METHODS AND COMPOSITIONS FOR INHIBITING PIN1 | |
EP2539444A4 (en) | COMPOSITIONS AND METHODS FOR THE PRODUCTION OF L-HOMOALANINE | |
EP2672822A4 (en) | METHOD AND COMPOSITIONS FOR IMPROVING COGNITIVE FUNCTIONS | |
HK1191569A1 (zh) | 依帕司他的改進釋放組合物或其衍生物及其使用方法 | |
PL2731963T3 (pl) | Kompozycje i sposoby do immunomodulacji | |
ZA201308892B (en) | Compositions and methods | |
HK1254904B (zh) | 用於改變xlhed表型的組合物和方法 | |
EP2797614A4 (en) | COMPOSITIONS AND METHODS FOR INHIBITING INTERACTION BETWEEN CFTR AND CAL | |
ZA201403281B (en) | Methods and compositions for neuroprotection | |
EP2766357A4 (en) | MESOBILIVERDINE COMPOSITIONS AND METHOD THEREFOR | |
EP3603631C0 (en) | METHODS AND COMPOSITIONS FOR TREATING DIVERTICULOSIS | |
GB201020357D0 (en) | Compounds and methods of making the same | |
GB201116340D0 (en) | Compositions and methods | |
AU2011901902A0 (en) | Methods and compositions for the treatment of melanoma | |
WO2013006854A9 (en) | Compositions and methods for treating enterobacteriaceae | |
AU2011903137A0 (en) | Compounds and methods of their use - IV |